company background image
IGN

Inno-Gene WSE:IGN Stock Report

Last Price

zł6.77

Market Cap

zł38.6m

7D

-4.9%

1Y

-33.7%

Updated

29 Sep, 2022

Data

Company Financials
IGN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

IGN Stock Overview

Inno-Gene S.A. provides genetic diagnostic solutions in Poland.

Inno-Gene S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inno-Gene
Historical stock prices
Current Share Pricezł6.77
52 Week Highzł14.00
52 Week Lowzł4.50
Beta1.49
1 Month Change-15.27%
3 Month Change-16.42%
1 Year Change-33.69%
3 Year Change207.73%
5 Year Change113.57%
Change since IPO57.44%

Recent News & Updates

Jul 25
Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today

Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Shareholder Returns

IGNPL Life SciencesPL Market
7D-4.9%-0.7%-7.9%
1Y-33.7%-40.9%-35.7%

Return vs Industry: IGN exceeded the Polish Life Sciences industry which returned -38.7% over the past year.

Return vs Market: IGN matched the Polish Market which returned -33.1% over the past year.

Price Volatility

Is IGN's price volatile compared to industry and market?
IGN volatility
IGN Average Weekly Movement13.4%
Life Sciences Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: IGN is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IGN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
201015Jacek Wojciechowiczhttps://www.inno-gene.pl

Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements genetic tests for prenatal diagnostic, which are based on next generation sequencing technology; and diagnostic algorithm for prophylaxis and personalized therapies for HPV-dependent solid tumors.

Inno-Gene S.A. Fundamentals Summary

How do Inno-Gene's earnings and revenue compare to its market cap?
IGN fundamental statistics
Market Capzł38.60m
Earnings (TTM)zł2.70m
Revenue (TTM)zł32.70m

14.3x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IGN income statement (TTM)
Revenuezł32.70m
Cost of Revenuezł9.30m
Gross Profitzł23.39m
Other Expenseszł20.70m
Earningszł2.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 14, 2022

Earnings per share (EPS)0.47
Gross Margin71.55%
Net Profit Margin8.25%
Debt/Equity Ratio0.0%

How did IGN perform over the long term?

See historical performance and comparison